alexa A Preclinical Overview On Gold (III) Compounds In The Forefront Of The Targeted Anticancer Therapy
ISSN: 2157-7013

Journal of Cell Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th World Congress on Cell Science & Stem Cell Research
June 24-26, 2014 Valencia Conference Centre, Valencia, Spain

Chiara Nardon, Leonardo Brustolin, Mauro Coluccia3 and D Fregona
ScientificTracks Abstracts: J Cell Sci Ther
DOI: 10.4172/2157-7013.S1.028
Abstract
I n the last four decades the drug cisplatin has been widely used in oncology despite of its toxicity, in particular nephrotoxicity, due to the high affinity of the soft metal center Pt(II) toward renal sulfur- and selenium-containing enzymes, thus affecting their catalytic processes. Taking into account the severe toxicological profile of cisplatin and the peculiar chemical properties of Pt (II), a number of metal compounds with encouraging antitumor activity and reduced toxicity compared to the reference drug have been recently designed, synthetized and biologically studied. In designing these coordination compounds, we replaced the Pt(II) and the two ammonia ligands were replaced with Au(III), Cu(II) or Ru (III) and a dithiocarbamato (DTC) moiety, respectively. Among all the studied complexes, our Au (III)-based potential chemotherapeutics showed a particularly promising chemotherapeutic index. On the other hand, the bidentate DTC ligand is able to widely stabilize metal ions owing to its electron-donating capability, thus hindering the ligand-metal decomposition that could give rise to non-specific metal reactivity in healthy tissues. Furthermore, the presence of sulfur donor atoms in the DTC ligand prevents the metal from interacting with thiol-containing biomolecules (trans effect), resulting in reduced or even absent side-toxicity. So far, researches on gold(III)-dithiocarbamato derivatives of aminoacids and oligopeptides have been carried out. These compounds generally showed higher antitumor activity than cisplatin and no cross-resistance to the reference drug on several human tumor cell lines. In vivo studies, on breast cancer MDA-MB-231 and prostate cancer PC3 xenografts, showed a reduction of 53% and 70% in tumor volume respectively, with neither decreased activity nor weight loss. The in vivo acute toxicity by i.v. and oral administration routes recording remarkable results. No signs of toxicity have been observed during the study in any of the treated animals. It is worth highlighting that body weight for any mouse was constant or increased during the 14-day observation period. Along with the antiblastic activity against breast cancer, a transcriptomic study has been performed to yield a deep mechanistic understanding of what biochemical pathways, crosstalks and feedbacks are affected by our gold(III) compounds
Biography
Chiara Nardon completed her PhD (2013) at the University of Padova (Italy) during which she spent 6 months at Karmanos Cancer Institute in Detroit (USA). Her research interests are mainly focused on studying new metal-based anticancer agents. She has been awarded with several Italian and international prizes and fellowships including being worldwide selected among the 600 final participants in the 63 rd Meeting of Nobel Laureates. The magazine Scientific American has defined her among the young scientists who represent the future of chemistry. She is member of ACS, SCI and CIRCMSB societies and co-guest Editor of the Journal of Nanoscience and Nanotechnology
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]line.com

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords